A5049755216- Glioma Diagnosis and Treatment
- Epigenetics and DNA Methylation
- Mathematical Biology Tumor Growth
- Chemokine receptors and signaling
- Cancer, Hypoxia, and Metabolism
- Cancer Genomics and Diagnostics
- MicroRNA in disease regulation
- Bioinformatics and Genomic Networks
- Single-cell and spatial transcriptomics
- Cancer-related molecular mechanisms research
- Brain Metastases and Treatment
- RNA Interference and Gene Delivery
- Circular RNAs in diseases
- Gene Regulatory Network Analysis
- Cancer Mechanisms and Therapy
- Chemical Synthesis and Reactions
- Cancer therapeutics and mechanisms
- CAR-T cell therapy research
- Autophagy in Disease and Therapy
- Extracellular vesicles in disease
- Immune cells in cancer
- Cancer Cells and Metastasis
- Mesoporous Materials and Catalysis
- Microfluidic and Bio-sensing Technologies
- Pluripotent Stem Cells Research
Swedish Medical Center
2012-2024
Neuroscience Institute
2016-2024
Ivy Foundation
2021
Neurosciences Institute
2013
Glioblastoma is an aggressive brain tumor that carries a poor prognosis. The tumor's molecular and cellular landscapes are complex, their relationships to histologic features routinely used for diagnosis unclear. We present the Ivy Atlas, anatomically based transcriptional atlas of human glioblastoma aligns individual with genomic alterations gene expression patterns, thus assigning information most important morphologic hallmarks tumor. its clinical database freely accessible online data...
// Parvinder Hothi 1 , Timothy J. Martins 2 LiPing Chen Loic Deleyrolle 3 Jae-Geun Yoon Brent Reynolds and Greg Foltz The Ben Catherine Ivy Center for Advanced Brain Tumor Treatment, Swedish Neuroscience Institute, Seattle, WA, USA Quellos High-throughput Screening Core, UW Medicine, McKnight University of Florida, Gainesville, FL, Correspondence: Foltz, email: Keywords : disulfiram, glioblastoma, high-throughput chemical screens, stem cells Received October 12, 2012, Accepted 21, Published...
Optimal treatment of brain metastases is often hindered by limitations in diagnostic capabilities. To meet this challenge, here we profile DNA methylomes the three most frequent types metastases: melanoma, breast, and lung cancers (n = 96). Using supervised machine learning integration from normal, primary, metastatic tumor specimens 1860), unravel epigenetic signatures specific to each type constructed a three-step methylation-based classifier (BrainMETH) that categorizes according tissue...
// Biaoyang Lin 1, 2, 3 , Hwahyung Lee 4 Jae-Geun Yoon Anup Madan 4, 6 Elizabeth Wayner Sanja Tonning Parvinder Hothi Brett Schroeder Ilya Ulasov Gregory Foltz Leroy Hood 5 Charles Cobbs 1 Cancer Institute (Key Laboratory of Prevention and Intervention, China National Ministry Education), The Second Affiliated Hospital, Zhejiang University School Medicine, Hangzhou, 310003, 2 Dept. Urology, Washington, Seattle, WA 98195, USA System Biology Division, Zhejiang-California International...
Abstract Glioblastoma multiforme (GBM) is the most common and lethal adult brain tumor. Resistance to standard radiation chemotherapy thought involve survival of GBM cancer stem cells (CSCs). To date, no single marker for identifying CSCs has been able capture diversity CSC populations, justifying needs additional markers better characterization. Employing targeted mass spectrometry, here we present five cell-surface HMOX1, SLC16A1, CADM1, SCAMP3, CLCC1 which were found be elevated in...
Poor prognosis and drug resistance in glioblastoma (GBM) can result from cellular heterogeneity treatment-induced shifts phenotypic states of tumor cells, including dedifferentiation into glioma stem-like cells (GSCs). This rare tumorigenic cell subpopulation resists temozolomide, undergoes proneural-to-mesenchymal transition (PMT) to evade therapy, drives recurrence. Through inference transcriptional regulatory networks (TRNs) patient-derived GSCs (PD-GSCs) at single-cell resolution, we...
Glioblastoma (GBM) is the most common primary brain tumor in adults. The poor prognosis and minimally successful treatments of these tumors indicates a need to identify new therapeutic targets. Therapy resistance GBMs attributed heterogeneity glioblastoma due genetic alterations functional subpopulations. Chemokine receptors CXCR4 CXCR7 play important roles progression various cancers although specific functions CXCL12−CXCR4−CXCR7 axis GBM are less characterized. In this study we examined...
Abstract Brain metastases (BM) are one the most lethal and poorly managed clinical complications in cancer patients. These secondary tumors represent common intracranial neoplasm adults, frequently originating from lung cancer, breast cutaneous melanoma. In primary brain tumors, such as gliomas, recent advances DNA methylation profiling have allowed for a comprehensive molecular classification. Such data provide prognostic information, addition to helping predict patient response specific...
// Ilya V. Ulasov 1, 4 , Nameeta Shah 1 Natalya Kaverina 2, 5 Hwahyang Lee Biaoyang Lin Andre Lieber 3 Zaira G. Kadagidze 2 Jae-Guen Yoon Brett Schroeder Parvinder Hothi Dhimankrishna Ghosh Anatoly Y. Baryshnikov Charles S. Cobbs Swedish Neuroscience Institute, Seattle, WA, 98122, USA NN. Blokhin Cancer Research Center, RAMN, Moscow, Russia, 115478 University of Washington, Institute Experimental Diagnostic and Biotherapy, Current address: Division Nephrology, 98109, Correspondence to:...
ABSTRACT Poor prognosis and drug resistance in glioblastoma (GBM) can result from cellular heterogeneity treatment-induced shifts phenotypic states of tumor cells, including dedifferentiation into glioma stem-like cells (GSCs). This rare tumorigenic cell subpopulation resists temozolomide, undergoes proneural-to-mesenchymal transition (PMT) to evade therapy, drives recurrence. Through inference transcriptional regulatory networks (TRNs) patient-derived GSCs (PD-GSCs) at single-cell...
ABSTRACT Grade IV glioma, formerly known as glioblastoma multiforme (GBM) is the most aggressive and lethal type of brain tumor, its treatment remains challenging in part due to extensive interpatient heterogeneity disease driving mechanisms lack prognostic predictive biomarkers. Using mechanistic inference node-edge relationship (MINER), we have analyzed multiomics profiles from 516 patients constructed an atlas causal drivers GBM (gbmMINER). The has delineated how 30 driver mutations act a...
Krishna Panchalingam1, Wendy Paramchuk1, Parvinder Hothi2, Nameeta Shah2, Leroy Hood3, Greg Foltz2 and Leo A. Behie1 1Pharmaceutical Production Research Facility (PPRF), Schulich School of Engineering, Calgary, Alberta 2Ben Catherine Ivy Center for Advanced Brain Tumour Treatment, Swedish Neuroscience Institute, Seattle, Washington 3Institute Systems Biology, 1Canada 2,3United States America
Abstract Optimal treatment of brain metastases is often hindered by limitations in diagnostic capabilities. To meet these challenges, we generated genome-scale DNA methylomes the three most frequent types metastases: melanoma, breast, and lung cancers (n=96). Using supervised machine learning integration multiple from normal, primary, metastatic tumor specimens (n=1,860), unraveled epigenetic signatures specific to each type constructed a three-step methylation-based classifier (BrainMETH)...
The failure of standard care treatment for patients diagnosed with glioblastoma (GBM) coupled the highly vascularized nature this solid tumor has led to consideration agents that target vascular endothelial growth factor (VEGF) or its receptors, as alternative therapeutic strategies disease. While early clinical studies determined recurrent GBMs respond favorably bevacizumab (BVZ), progression tumors after anti-VEGF targeted therapy is inevitable and in many instances disease presents a more...
Abstract Glioblastoma (GBM) is one of the most malignant and aggressive forms primary brain tumors. Current standard treatment options for patients diagnosed with GBM include surgical resection, radiation, chemotherapy. Since features an extensively vascularized solid tumor, anti-angiogenic agents have also been considered as a regimen patients. Indeed, evidence from clinical trials has shown that Bevacizumab (Avastin®), anti-VEGF monoclonal antibody, successfully reduces development tumor...
Abstract Glioblastoma (GBM) is the most aggressive and lethal type of brain tumor, its treatment remains challenging due to complexity underlying molecular mechanisms. Here, we present gbmMINER, a causal mechanistic transcriptional regulatory network model for GBM that integrates multi-omics clinical data with new quantization approach using MINER algorithm. gbmMINER accurately grouped 9,728 genes into 3,797 regulons identified 179 programs stratify 23 disease states, associated distinct...
Small molecules that target microtubules (MTs) represent promising therapeutics to treat certain types of cancer, including glioblastoma multiform (GBM). We synthesized modified carbazoles and evaluated their antitumor activity in GBM cells culture. Modified with an ethyl moiety linked the nitrogen carbazole a carbonyl distinct biaromatic rings exhibited remarkably different killing activities human cell lines patient-derived cells, IC50 values from 67 > 10,000 nM. Measures tubulin coupled...